Iqoniko Appointed Capital Market Partner of HEP-one GmbH for Planned Stock Market Listing
Dubai (pts006/31.07.2026/06:35)
Iqoniko is pleased to announce that it has been mandated by HEP-one GmbH as a capital market partner to support the company on its path to a planned stock market listing.
As a capital market partner, Iqoniko will take on a central role in preparing HEP-one GmbH's access to the capital market, developing a financing concept for the upcoming clinical and regulatory steps, and positioning the company with investors and industry partners.
HEP-one develops therapeutic and diagnostic approaches for inflammatory and post-infectious diseases. The core of the platform is HEP-1, a human ezrin peptide that is being investigated for its inflammation-modulating, antiviral, and tissue-regenerative properties. Its development programs address Long COVID/Post-COVID syndrome, ME/CFS, and ulcerative colitis.
"The planned stock market listing is intended to support the financing of the next clinical and regulatory development steps, as well as the expansion of international research and industry partnerships," explains Dr. Ingolf Piechota, Project Manager of HEP-one GmbH.
"We are particularly proud of this mandate and are delighted to be part of this innovation. If our work can contribute, even marginally, to making life a little easier for many Long COVID patients, then this is one of the most significant mandates for us," says Miguel Moura, Iqoniko.
HEP-one plans to utilize the collaboration with Iqoniko over the coming months for further steps toward capital market readiness.
About HEP-one GmbH
HEP-one GmbH develops therapeutic and diagnostic approaches for inflammatory and post-infectious diseases, with the drug candidate HEP-1 serving as the central element of the platform.
About Iqoniko Group
The Iqoniko Group is an internationally active capital markets and strategy advisory firm with offices in London and Dubai. Its core focus includes going-public processes, stock exchange listings, fundraising, and the strategic capital markets positioning of growth-oriented companies. As an approved capital markets partner (Iqoniko Ltd.), the group provides support to startups, publicly listed small- and mid-cap companies, and investment firms— ranging from capital markets entry preparation to sustainable positioning with investors.
(end)| Aussender: | Iqoniko LLC FZ |
| Ansprechpartner: | Moura |
| Tel.: | +971 452 478 75 |
| E-Mail: | office@iqoniko.com |
| Website: | www.iqoniko.com |
